- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06121843
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
April 25, 2024 updated by: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
111
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: BMS Study Connect Contact Center www.BMSStudyConnect.com
- Phone Number: 855-907-3286
- Email: Clinical.Trials@bms.com
Study Contact Backup
- Name: First line of the email MUST contain NCT # and Site #.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294-3300
- Recruiting
- University of Alabama at Birmingham
-
Contact:
- Susan Bal, Site 0008
- Phone Number: 205-934-1908
-
-
California
-
Duarte, California, United States, 91010
- Not yet recruiting
- City of Hope Comprehensive Cancer Center
-
Contact:
- Myo Htut, Site 0028
- Phone Number: 626-256-4673
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Not yet recruiting
- Beth Israel Deaconess Medical Center
-
Contact:
- Jessica Liegel, Site 0027
- Phone Number: 617-667-9922
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- Not yet recruiting
- Local Institution - 0010
-
Contact:
- Site 0010
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan Kettering Cancer Center
-
Contact:
- Sham Mailankody, Site 0012
- Phone Number: 646-608-3712
-
New York, New York, United States, 10032
- Recruiting
- Columbia University Irving Medical Center
-
Contact:
- Divaya Bhutani, Site 0009
- Phone Number: 646-317-6303
-
New York, New York, United States, 10016
- Recruiting
- Laura and Isaac Perlmutter Cancer Center
-
Contact:
- Jingmei Hsu, Site 0022
- Phone Number: 646-501-4848
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- Withdrawn
- Local Institution - 0023
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- University of Texas MD Anderson Cancer Center
-
Contact:
- Krina Patel, Site 0003
- Phone Number: 713-792-6662
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1 and Part 2) or at least 1 but not greater than 3 prior anti-myeloma treatment regimens (Part 2)
- Measurable multiple myeloma (MM)
- Eastern Cooperative Oncology Group performance status of 0-1
Exclusion Criteria:
- Condition that confounds the ability to interpret data from the study
- Known active or history of central nervous system (CNS) involvement of MM
Note: Other protocol-defined inclusion/exclusion criteria apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A: BMS-986393 + Alnuctamab
|
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
Experimental: Arm B: BMS-986393 + Mezigdomide
|
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
Experimental: Arm C: BMS-986393 + Iberdomide
|
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of AEs leading to discontinuation
Time Frame: Up to 2 years
|
Up to 2 years
|
Incidence of adverse events (AEs)
Time Frame: Up to 2 years
|
Up to 2 years
|
Incidence of serious adverse events (SAEs)
Time Frame: Up to 2 years
|
Up to 2 years
|
Incidence of adverse events of special interest (AESI)
Time Frame: Up to 2 years
|
Up to 2 years
|
Number of Deaths
Time Frame: Up to 2 years
|
Up to 2 years
|
Establish recommended Phase 2 dose (RP2D)
Time Frame: Up to 2 years
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall response rate (ORR)
Time Frame: Up to 2 years
|
Up to 2 years
|
Complete response rate (CRR)
Time Frame: Up to 2 years
|
Up to 2 years
|
Very good partial response rate (VGPRR)
Time Frame: Up to 2 years
|
Up to 2 years
|
Maximum observed concentration (Cmax)
Time Frame: Up to 2 years
|
Up to 2 years
|
Time of maximum observed concentration (tmax)
Time Frame: Up to 2 years
|
Up to 2 years
|
Area under the concentration-time curve from time 0 to 28 days [AUC (0-28D)]
Time Frame: Up to 2 years
|
Up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 22, 2024
Primary Completion (Estimated)
August 1, 2028
Study Completion (Estimated)
August 1, 2028
Study Registration Dates
First Submitted
November 2, 2023
First Submitted That Met QC Criteria
November 2, 2023
First Posted (Actual)
November 8, 2023
Study Record Updates
Last Update Posted (Actual)
April 26, 2024
Last Update Submitted That Met QC Criteria
April 25, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
- CA088-1005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria.
Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Mezigdomide
-
Bristol-Myers SquibbCompletedHepatic ImpairmentUnited States
-
CelgeneNot yet recruitingRenal ImpairmentUnited States
-
CelgeneActive, not recruitingMultiple MyelomaUnited States, Canada, Denmark, Australia, Belgium, Finland, Greece, Japan, Korea, Republic of, Spain, United Kingdom
-
Bristol-Myers SquibbRecruitingRelapsed or Refractory Multiple MyelomaUnited States, Austria, Denmark, Canada, Australia, China, Spain, Germany, United Kingdom, Hungary, Taiwan, Israel, Japan, India, Norway, Brazil, Italy, Greece, Korea, Republic of, Colombia, Singapore, Netherlands, Argentina, Hong Kong, Romani... and more
-
CelgeneRecruitingMultiple MyelomaUnited States, Israel, Spain, Denmark, France, Germany, Netherlands
-
CelgeneActive, not recruitingMultiple MyelomaUnited States, Canada, Italy, Czechia, Denmark, France, Germany, Greece, Spain
-
Kathleen DorritieBristol-Myers SquibbRecruitingRelapsed and Refractory Multiple MyelomaUnited States
-
CelgeneRecruitingRelapsed or Refractory Multiple MyelomaUnited States, Australia, Italy, China, Spain, Germany, Romania, Korea, Republic of, Japan, United Kingdom, Czechia, Finland, France, Greece, Argentina, Belgium, Austria, Portugal, Israel, Poland, Brazil, Turkey, Canada, Ireland, New Zealand and more
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMultiple MyelomaUnited States
-
Karyopharm Therapeutics IncBristol-Myers SquibbActive, not recruitingMultiple MyelomaUnited States, Canada